My Treatment Approach: Optimal Second- and Third-Line Treatment Options of cGVHD | Supplements and Featured Publications

The My Treatment Approach: Optimal Second- and Third-Line Treatment Options of cGVHD publication covers some of the latest and practice-changing advances in the treatment for patients with chronic graft-vs-host disease following recent regulatory decisions and data read outs from pivotal clinical trials, as well as expert insights on how they approach therapy on an individualized basis.


Dr. Chen on Risk Factors for Developing cGVHD

December 01, 2021

Video

Yi-Bin Chen, MD, discusses risk factors for developing chronic graft-vs-host disease in patients who receive an allogeneic transplant.

Dr. Neumann on Tapering Steroids in cGVHD

December 01, 2021

Video

Joyce L. Neumann, PhD, APRN, AOCN, BMTCN, FAAN, discusses tapering steroids for patients with chronic graft-vs-host disease.

Variable Chronic GVHD Presentations Stress the Need for Close Symptom Monitoring

November 22, 2021

Article

Joyce L. Neumann, PhD, APRN, AOCN, BMTCN, FAAN, discusses the variability in cGVHD presentation, key symptoms of the disease in patients with cancer, and how the field is navigating between available therapies.

Long-Term Toxicity With Frontline Steroids Remains a Key Consideration of Chronic GVHD Management

November 19, 2021

Article

Corey S. Cutler, MD, MPH, FRCPC, discusses the diagnostic and treatment landscape of chronic graft-vs-host disease.

Preventive and Early Intervention Strategies Among Next Steps in cGVHD Management

October 28, 2021

Article

As the armamentarium continues expanding for the treatment of patients with chronic graft-vs-host disease, research is ongoing to determine whether earlier integration of novel therapies, such as ruxolitinib, could yield better response rates for patients.

cGVHD Paradigm Gains Systemic Options Beyond Steroids, But Real-World Data Are Required

October 27, 2021

Article

Yi-Bin Chen, MD, discusses the nuances of diagnosing patients with cGVHD, the need for biomarkers to inform who is likely to develop the disease, the introduction of ruxolitinib and belumosudil to the paradigm, and future directions with novel strategies in the space.